vs

Side-by-side financial comparison of Axsome Therapeutics, Inc. (AXSM) and ZoomInfo Technologies Inc. (GTM). Click either name above to swap in a different company.

ZoomInfo Technologies Inc. is the larger business by last-quarter revenue ($319.1M vs $196.0M, roughly 1.6× Axsome Therapeutics, Inc.). ZoomInfo Technologies Inc. runs the higher net margin — 10.9% vs -14.6%, a 25.4% gap on every dollar of revenue. On growth, Axsome Therapeutics, Inc. posted the faster year-over-year revenue change (65.0% vs 3.2%). ZoomInfo Technologies Inc. produced more free cash flow last quarter ($127.1M vs $-18.7M). Over the past eight quarters, Axsome Therapeutics, Inc.'s revenue compounded faster (61.7% CAGR vs 1.4%).

Jazz Pharmaceuticals plc is a global biopharmaceutical company with a focus on oncology and neuroscience. It was founded in 2003 in California, United States and is now headquartered in Dublin, Ireland.

ZoomInfo Technologies Inc. is a registered data broker in the United States. The company collects and sells personal data, both public and private, through various means of data and web scraping. Information about business entities like companies and departments are also collected and offered. These personal information are available for sale, where other businesses can use the collected data for targeted marketing.

AXSM vs GTM — Head-to-Head

Bigger by revenue
GTM
GTM
1.6× larger
GTM
$319.1M
$196.0M
AXSM
Growing faster (revenue YoY)
AXSM
AXSM
+61.8% gap
AXSM
65.0%
3.2%
GTM
Higher net margin
GTM
GTM
25.4% more per $
GTM
10.9%
-14.6%
AXSM
More free cash flow
GTM
GTM
$145.8M more FCF
GTM
$127.1M
$-18.7M
AXSM
Faster 2-yr revenue CAGR
AXSM
AXSM
Annualised
AXSM
61.7%
1.4%
GTM

Income Statement — Q4 FY2025 vs Q4 FY2025

Metric
AXSM
AXSM
GTM
GTM
Revenue
$196.0M
$319.1M
Net Profit
$-28.6M
$34.7M
Gross Margin
84.0%
Operating Margin
-13.8%
17.0%
Net Margin
-14.6%
10.9%
Revenue YoY
65.0%
3.2%
Net Profit YoY
61.9%
137.7%
EPS (diluted)
$-0.55
$0.11

Green = leading value per metric. Periods may differ when fiscal calendars don't align.

8-Quarter Revenue & Profit Trend

Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.

Revenue
AXSM
AXSM
GTM
GTM
Q4 25
$196.0M
$319.1M
Q3 25
$171.0M
$318.0M
Q2 25
$150.0M
$306.7M
Q1 25
$121.5M
$305.7M
Q4 24
$118.8M
$309.1M
Q3 24
$104.8M
$303.6M
Q2 24
$87.2M
$291.5M
Q1 24
$75.0M
$310.1M
Net Profit
AXSM
AXSM
GTM
GTM
Q4 25
$-28.6M
$34.7M
Q3 25
$-47.2M
$38.7M
Q2 25
$-48.0M
$24.0M
Q1 25
$-59.4M
$26.8M
Q4 24
$-74.9M
$14.6M
Q3 24
$-64.6M
$23.8M
Q2 24
$-79.3M
$-24.4M
Q1 24
$-68.4M
$15.1M
Gross Margin
AXSM
AXSM
GTM
GTM
Q4 25
84.0%
Q3 25
83.7%
Q2 25
83.9%
Q1 25
84.5%
Q4 24
82.8%
Q3 24
84.4%
Q2 24
84.3%
Q1 24
86.0%
Operating Margin
AXSM
AXSM
GTM
GTM
Q4 25
-13.8%
17.0%
Q3 25
-27.0%
21.2%
Q2 25
-24.5%
17.5%
Q1 25
-46.9%
16.5%
Q4 24
-61.1%
10.0%
Q3 24
-59.8%
14.3%
Q2 24
-89.5%
-6.9%
Q1 24
-89.7%
13.9%
Net Margin
AXSM
AXSM
GTM
GTM
Q4 25
-14.6%
10.9%
Q3 25
-27.6%
12.2%
Q2 25
-32.0%
7.8%
Q1 25
-48.9%
8.8%
Q4 24
-63.1%
4.7%
Q3 24
-61.7%
7.8%
Q2 24
-91.0%
-8.4%
Q1 24
-91.1%
4.9%
EPS (diluted)
AXSM
AXSM
GTM
GTM
Q4 25
$-0.55
$0.11
Q3 25
$-0.94
$0.12
Q2 25
$-0.97
$0.07
Q1 25
$-1.22
$0.08
Q4 24
$-1.54
$0.04
Q3 24
$-1.34
$0.07
Q2 24
$-1.67
$-0.07
Q1 24
$-1.44
$0.04

Balance Sheet & Financial Strength

Snapshot of each company's liquidity, leverage and book value from the latest quarter.

Metric
AXSM
AXSM
GTM
GTM
Cash + ST InvestmentsLiquidity on hand
$322.9M
$179.9M
Total DebtLower is stronger
$1.3B
Stockholders' EquityBook value
$88.3M
$1.5B
Total Assets
$689.8M
$6.4B
Debt / EquityLower = less leverage
0.88×

8-quarter trend — quarters aligned by calendar period.

Cash + ST Investments
AXSM
AXSM
GTM
GTM
Q4 25
$322.9M
$179.9M
Q3 25
$325.3M
$135.0M
Q2 25
$303.0M
$176.9M
Q1 25
$300.9M
$140.5M
Q4 24
$315.4M
$139.9M
Q3 24
$327.3M
$147.7M
Q2 24
$315.7M
$399.3M
Q1 24
$331.4M
$440.2M
Total Debt
AXSM
AXSM
GTM
GTM
Q4 25
$1.3B
Q3 25
$1.3B
Q2 25
$1.3B
Q1 25
$1.2B
Q4 24
$1.2B
Q3 24
$1.2B
Q2 24
$1.2B
Q1 24
$1.2B
Stockholders' Equity
AXSM
AXSM
GTM
GTM
Q4 25
$88.3M
$1.5B
Q3 25
$73.7M
$1.5B
Q2 25
$73.1M
$1.6B
Q1 25
$53.2M
$1.6B
Q4 24
$57.0M
$1.7B
Q3 24
$92.9M
$1.7B
Q2 24
$102.9M
$1.9B
Q1 24
$144.0M
$2.0B
Total Assets
AXSM
AXSM
GTM
GTM
Q4 25
$689.8M
$6.4B
Q3 25
$669.3M
$6.4B
Q2 25
$639.8M
$6.5B
Q1 25
$596.7M
$6.4B
Q4 24
$568.5M
$6.5B
Q3 24
$561.5M
$6.4B
Q2 24
$548.2M
$6.7B
Q1 24
$545.7M
$6.8B
Debt / Equity
AXSM
AXSM
GTM
GTM
Q4 25
0.88×
Q3 25
0.87×
Q2 25
0.85×
Q1 25
0.75×
Q4 24
0.72×
Q3 24
0.74×
Q2 24
0.66×
Q1 24
0.61×

Cash Flow & Capital Efficiency

How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.

Metric
AXSM
AXSM
GTM
GTM
Operating Cash FlowLast quarter
$-18.7M
$143.5M
Free Cash FlowOCF − Capex
$-18.7M
$127.1M
FCF MarginFCF / Revenue
-9.6%
39.8%
Capex IntensityCapex / Revenue
0.0%
5.1%
Cash ConversionOCF / Net Profit
4.14×
TTM Free Cash FlowTrailing 4 quarters
$-93.9M
$389.3M

8-quarter trend — quarters aligned by calendar period.

Operating Cash Flow
AXSM
AXSM
GTM
GTM
Q4 25
$-18.7M
$143.5M
Q3 25
$1.0M
$93.8M
Q2 25
$-32.4M
$108.9M
Q1 25
$-43.4M
$119.2M
Q4 24
$-26.2M
$109.0M
Q3 24
$-18.6M
$18.2M
Q2 24
$-30.1M
$126.3M
Q1 24
$-53.5M
$115.9M
Free Cash Flow
AXSM
AXSM
GTM
GTM
Q4 25
$-18.7M
$127.1M
Q3 25
$988.0K
$70.9M
Q2 25
$-32.4M
$86.9M
Q1 25
$-43.7M
$104.4M
Q4 24
$-26.2M
$85.6M
Q3 24
$-18.7M
$600.0K
Q2 24
$-30.2M
$115.2M
Q1 24
$-53.6M
$103.1M
FCF Margin
AXSM
AXSM
GTM
GTM
Q4 25
-9.6%
39.8%
Q3 25
0.6%
22.3%
Q2 25
-21.6%
28.3%
Q1 25
-36.0%
34.2%
Q4 24
-22.1%
27.7%
Q3 24
-17.9%
0.2%
Q2 24
-34.6%
39.5%
Q1 24
-71.4%
33.2%
Capex Intensity
AXSM
AXSM
GTM
GTM
Q4 25
0.0%
5.1%
Q3 25
0.0%
7.2%
Q2 25
0.0%
7.2%
Q1 25
0.3%
4.8%
Q4 24
0.0%
7.6%
Q3 24
0.1%
5.8%
Q2 24
0.1%
3.8%
Q1 24
0.1%
4.1%
Cash Conversion
AXSM
AXSM
GTM
GTM
Q4 25
4.14×
Q3 25
2.42×
Q2 25
4.54×
Q1 25
4.45×
Q4 24
7.47×
Q3 24
0.76×
Q2 24
Q1 24
7.68×

Financial Flow Comparison

Revenue → gross profit → operating profit → net profit for each company.

Related Comparisons